2-butoxy-7,8-dihydro-9-{2-[2-(4-hydroxylcarbonylpiperidin-1-yl)ethoxy]ethyl}-8-oxoadenine | 931097-01-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-butoxy-7,8-dihydro-9-{2-[2-(4-hydroxylcarbonylpiperidin-1-yl)ethoxy]ethyl}-8-oxoadenine
• 英文别名: 1-[2-[2-(6-amino-2-butoxy-8-oxo-7H-purin-9-yl)ethoxy]ethyl]piperidine-4-carboxylic acid
• CAS: 931097-01-7
• 化学式: C₁₉H₃₀N₆O₅
• 分子量: 422.484
• InChiKey: IURGMXNNZCGHIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  143
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• INDAZOLE DERIVATIVES FOR THE TREATMENT OF HSP90-INDUCED DISEASES
  申请人：Buchstaller Hans Peter

  公开号：US20090197882A1

  公开（公告）日：2009-08-06

  Novel indazole derivatives of the formula (I), in which R 1 -R 3 have the meanings indicated in Claim ( 1 ), are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

  式（I）中的新型吲唑衍生物，其中R1-R3具有权利要求书（1）中指示的含义，是HSP90抑制剂，可用于制备用于治疗HSP90起作用的疾病的药物。
• NOVEL ADENINE COMPOUND
  申请人：Hashimoto Kazuki

  公开号：US20090192153A1

  公开（公告）日：2009-07-30

  An adenine compound or its pharmaceutically acceptable salt as a medicament as shown following formula (1): wherein R 1 is optionally substituted alkyl group, etc., X is oxygen atom, etc., A is 4 to 8 membered optionally substituted saturated or unsaturated heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom and 0 to 1 sulfur atom, L 1 and L 2 are independently straight or branched chain alkylene, or a single bond, R 2 is optionally substituted alkyl group, etc.

  一种腺嘌呤化合物或其药学上可接受的盐作为药物，如下所示的公式（1）：其中，R1是可选的取代烷基等，X是氧原子等，A是4到8个成员的可选取代饱和或不饱和杂环基团，包含1到2个杂原子，选自1到3个氮原子，0到1个氧原子和0到1个硫原子，L1和L2是独立的直链或支链烷基，或单键，R2是可选的取代烷基等。
• US8722903B2
  申请人：——

  公开号：US8722903B2

  公开（公告）日：2014-05-13